Nanoparticle Delivery Platform

ImmuNova Biomed is focused on various immune intervention technologies, including peptide-based immunobiological nanomedicine, addressing critical health challenges in cancer. ImmuNova BioMed was established as a collaborative joint venture bringing together two leading experts from the pharmaceutical industry and scientific research fields. Our mission is to become a leader in the development of cutting-edge peptide-based therapies, innovative molecules and advanced biotechnological solutions based on nanomedicine. Our focus spans critical areas such as cancer, and immunologic diseases.

Nanomedicine

Our Expertise

At ImmuNova BioMed, we harness our extensive knowledge in nano-encapsulation and controlled release of active compounds. Our innovative approach includes developing targeted nanoparticles designed for the precise delivery of biological drugs and imaging agents, significantly enhancing treatment safety and efficacy.